Loading stock data…
908 Devices Inc (MASS)
$8.81+0.03 (+0.34%)
After Hours$8.81+0.00 (+0.00%)· Last close Jun 29
908 Devices Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
908 Devices Inc. in the Healthcare sector is trading at $8.81 with a market capitalization of $328M. Wall Street consensus targets $11.00 (2 analysts), implying a +24.9% move over the next 12 months. The stock is currently near its 52-week high of $9.34, remaining 26.2% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +24.9% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $13.38M↓ | $17.38M↑ | $14.01M↑ | $13.04M↑ | $11.78M |
| Gross Profit | $6.88M↓ | $9.15M↑ | $7.36M↑ | $6.37M↑ | $5.54M |
| Operating Income | -$6.50M↓ | -$3.17M↑ | -$5.62M↑ | -$8.37M↑ | -$8.53M |
| Net Income | -$11.96M↓ | $4.17M↑ | -$14.98M↓ | -$13.31M↓ | $43.60M |
Peer Comparison
JNJUNHPFE
Fundamentals
908 Devices Inc. provides purpose-built handheld mass spectrometry and fourier transform infrared (FTIR) devices for use in vital health and safety applications. The company's products include MX908, a handheld, battery-powered, and Mass Spec device ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$327.84M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-26.88%
Volume
Today's trading volume
231,303
Recent News
908 Devices (MASS) Upgraded to Buy: Here's Why
908 Devices (MASS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
908 Devices MASS Q1 2026 Earnings Transcript
On our last earnings call, we outlined 3 focus areas for 2026, scaling our proven platforms, extending our handheld leadership through differentiated capabilities and disciplined innovation and strengthening revenue durability through recurring and program-based opportunities. This morning, we are excited to announce the acquisition of NIRLAB AG. This acquisition brings together highly complementary drug detection capabilities, increases our international revenue mix and provides a high retention recurring software subscription model.
908 Devices Inc. Q1 2026 Earnings Call Summary
Moby summary of 908 Devices Inc.'s Q1 2026 earnings call
908 Devices Q1 Earnings Call Highlights
908 Devices (NASDAQ:MASS) reported first-quarter 2026 revenue of $13.4 million, up 14% year over year, as the company pointed to continued momentum in U.S. state and local demand and announced a new acquisition aimed at expanding its handheld narcotics detection portfolio and recurring revenue base.
908 Devices Inc. (MASS) Reports Q1 Loss, Tops Revenue Estimates
908 Devices (MASS) delivered earnings and revenue surprises of 0.00% and +1.66%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?